Amphastar Pharmaceuticals (AMPH) Income from Continuing Operations (2016 - 2025)

Amphastar Pharmaceuticals has reported Income from Continuing Operations over the past 13 years, most recently at 58416000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 58416000.0 for Q4 2025, up 34.67% from a year ago — trailing twelve months through Dec 2025 was 132081000.0 (down 20.2% YoY), and the annual figure for FY2025 was 132081000.0, down 20.2%.
  • Income from Continuing Operations for Q4 2025 was 58416000.0 at Amphastar Pharmaceuticals, up from 17350000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for AMPH hit a ceiling of 58416000.0 in Q4 2025 and a floor of 145250000.0 in Q4 2023.
  • Median Income from Continuing Operations over the past 5 years was 25855000.0 (2023), compared with a mean of 14387150.0.
  • Biggest five-year swings in Income from Continuing Operations: soared 703.36% in 2021 and later tumbled 494.19% in 2022.
  • Amphastar Pharmaceuticals' Income from Continuing Operations stood at 23652000.0 in 2021, then tumbled by 494.19% to 93234000.0 in 2022, then tumbled by 55.79% to 145250000.0 in 2023, then soared by 129.86% to 43378000.0 in 2024, then soared by 34.67% to 58416000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 58416000.0 (Q4 2025), 17350000.0 (Q3 2025), and 31030000.0 (Q2 2025) per Business Quant data.